Wednesday, October 27, 2021
Axcella Health (AXLA)
Axcella Announces Plans For COVID-19 Long-Haulers
Axcella Health Inc. is a clinical-stage biotechnology company focused on treating complex diseases and improvinge health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company’s pipeline includes two lead therapeutic candidates:, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy (OHE) , and AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH).
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Raising Price Target Axcella Therapeutics held an R&D Day to review the company’s current Phase 2 trials and development platform. It also announced plans for a Phase 2 clinical trial to test AXA1125 in Long COVID (Post-Acute Sequelae of COVID-19). In view of this new trial and its market potential, we are raising our price target.
Research and Development Day Reviewed Trials and Product Design The company reviewed how its products target multiple disease drivers rather than a single target in a disease pathway. Preclinical studies showed increases in fatty acid oxidation, restoration of cellular homeostasis, and reduced inflammation. These actions improve mitochondrial function and increase energetic efficiency, resulting …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
